FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161444897> ?p ?o ?g. }

• W2161444897 endingPage "1328" @default.
• W2161444897 startingPage "1320" @default.
• W2161444897 abstract "Phase I biotransformation of Trichostatin A (TSA), a histone deacetylase inhibitor with promising antifibrotic and antitumoral properties, was investigated in rat and human liver microsomes and in suspensions of rat hepatocytes. TSA (50 micro M) was readily and completely metabolized by rat hepatocytes in suspension (2 x 10(6) cells/ml), whereafter its phase I metabolites were separated by high-performance liquid chromatography and detected with simultaneous UV and electrospray ionization mass spectrometry (ESI-MS). ESI tandem mass spectrometry (ESI-MS/MS) was used to identify the metabolites. Two major phase I biotransformation pathways in rat hepatocytes were shown to be N-demethylation and reduction of the hydroxamic acid function to its corresponding amide. N-monodemethylated TSA and TSA amide were preferentially formed during the first 20 min of exposure, and N-monodemethylated TSA amide appeared as the main metabolite after a 30 min incubation period. At this time, virtually all TSA had been metabolized. Trichostatic acid, N-monodemethylated Trichostatic acid, and N-didemethylated TSA were identified as minor metabolites. Longer incubation led to the formation of N-didemethylated TSA amide as the main metabolite. Lower concentrations of TSA (5 and 25 micro M) formed relatively higher amounts of N-demethylated, nonreduced metabolites. Incubations of TSA with rat and human microsomal suspensions, however, led to an incomplete biotransformation with the formation of two major metabolites, N-mono- and N-didemethylated TSA. Traces of Trichostatic acid, TSA amide, N-mono- and N-didemethylated TSA amide were also detected. This study is the first to show that TSA undergoes intensive phase I biotransformation in rat hepatocytes. This has important consequences for its potential development as a drug, since rapid biotransformation resulting in a short exposure to the pharmacologically active parent compound, and a complex mixture of metabolites is usually not desired. Further biotransformation studies of TSA and structural analogs with antitumoral and antifibrotic properties need to be performed in cultured intact hepatocytes, in particular since one of the major phase I biotransformation pathways is catalyzed by nonmicrosomal enzymes." @default.
• W2161444897 created "2016-06-24" @default.
• W2161444897 creator A5008668373 @default.
• W2161444897 creator A5008915422 @default.
• W2161444897 creator A5030751631 @default.
• W2161444897 creator A5045862213 @default.
• W2161444897 creator A5064093167 @default.
• W2161444897 creator A5076184988 @default.
• W2161444897 creator A5081672198 @default.
• W2161444897 date "2002-12-01" @default.
• W2161444897 modified "2023-10-16" @default.
• W2161444897 title "Major Phase I Biotransformation Pathways of Trichostatin A in Rat Hepatocytes and in Rat and Human Liver Microsomes" @default.
• W2161444897 cites W1550565578 @default.
• W2161444897 cites W1563624749 @default.
• W2161444897 cites W1587947784 @default.
• W2161444897 cites W1967089707 @default.
• W2161444897 cites W1985851210 @default.
• W2161444897 cites W1988784224 @default.
• W2161444897 cites W1991172705 @default.
• W2161444897 cites W1996086517 @default.
• W2161444897 cites W1998176369 @default.
• W2161444897 cites W2024647324 @default.
• W2161444897 cites W2031241298 @default.
• W2161444897 cites W2041564487 @default.
• W2161444897 cites W2046083229 @default.
• W2161444897 cites W2047131058 @default.
• W2161444897 cites W2071513872 @default.
• W2161444897 cites W2072375912 @default.
• W2161444897 cites W2082579037 @default.
• W2161444897 cites W2087831520 @default.
• W2161444897 cites W2089689060 @default.
• W2161444897 cites W2102968881 @default.
• W2161444897 cites W2135085078 @default.
• W2161444897 cites W2135830745 @default.
• W2161444897 cites W2145109415 @default.
• W2161444897 cites W2165452325 @default.
• W2161444897 cites W2398581313 @default.
• W2161444897 cites W4239125898 @default.
• W2161444897 cites W4293247451 @default.
• W2161444897 cites W50324694 @default.
• W2161444897 doi "https://doi.org/10.1124/dmd.30.12.1320" @default.
• W2161444897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12433798" @default.
• W2161444897 hasPublicationYear "2002" @default.
• W2161444897 type Work @default.
• W2161444897 sameAs 2161444897 @default.
• W2161444897 citedByCount "46" @default.
• W2161444897 countsByYear W21614448972012 @default.
• W2161444897 countsByYear W21614448972013 @default.
• W2161444897 countsByYear W21614448972014 @default.
• W2161444897 countsByYear W21614448972018 @default.
• W2161444897 countsByYear W21614448972019 @default.
• W2161444897 countsByYear W21614448972020 @default.
• W2161444897 crossrefType "journal-article" @default.
• W2161444897 hasAuthorship W2161444897A5008668373 @default.
• W2161444897 hasAuthorship W2161444897A5008915422 @default.
• W2161444897 hasAuthorship W2161444897A5030751631 @default.
• W2161444897 hasAuthorship W2161444897A5045862213 @default.
• W2161444897 hasAuthorship W2161444897A5064093167 @default.
• W2161444897 hasAuthorship W2161444897A5076184988 @default.
• W2161444897 hasAuthorship W2161444897A5081672198 @default.
• W2161444897 hasConcept C104317684 @default.
• W2161444897 hasConcept C150194340 @default.
• W2161444897 hasConcept C181199279 @default.
• W2161444897 hasConcept C185592680 @default.
• W2161444897 hasConcept C190727270 @default.
• W2161444897 hasConcept C192989942 @default.
• W2161444897 hasConcept C202199734 @default.
• W2161444897 hasConcept C25642318 @default.
• W2161444897 hasConcept C2777477808 @default.
• W2161444897 hasConcept C2777865847 @default.
• W2161444897 hasConcept C2778305200 @default.
• W2161444897 hasConcept C2778439535 @default.
• W2161444897 hasConcept C27881333 @default.
• W2161444897 hasConcept C43617362 @default.
• W2161444897 hasConcept C55493867 @default.
• W2161444897 hasConcept C62231903 @default.
• W2161444897 hasConcept C64927066 @default.
• W2161444897 hasConcept C87644729 @default.
• W2161444897 hasConceptScore W2161444897C104317684 @default.
• W2161444897 hasConceptScore W2161444897C150194340 @default.
• W2161444897 hasConceptScore W2161444897C181199279 @default.
• W2161444897 hasConceptScore W2161444897C185592680 @default.
• W2161444897 hasConceptScore W2161444897C190727270 @default.
• W2161444897 hasConceptScore W2161444897C192989942 @default.
• W2161444897 hasConceptScore W2161444897C202199734 @default.
• W2161444897 hasConceptScore W2161444897C25642318 @default.
• W2161444897 hasConceptScore W2161444897C2777477808 @default.
• W2161444897 hasConceptScore W2161444897C2777865847 @default.
• W2161444897 hasConceptScore W2161444897C2778305200 @default.
• W2161444897 hasConceptScore W2161444897C2778439535 @default.
• W2161444897 hasConceptScore W2161444897C27881333 @default.
• W2161444897 hasConceptScore W2161444897C43617362 @default.
• W2161444897 hasConceptScore W2161444897C55493867 @default.
• W2161444897 hasConceptScore W2161444897C62231903 @default.
• W2161444897 hasConceptScore W2161444897C64927066 @default.
• W2161444897 hasConceptScore W2161444897C87644729 @default.
• W2161444897 hasIssue "12" @default.
• W2161444897 hasLocation W21614448971 @default.

• next